Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning

Lung Cancer Clinical Trial

Official title:

Early Detection of Lung Cancer in a High-Risk Population Defined by Pulmonary Function Testing, Biomarkers, and Computerized Tomography Scanning

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00596310
• Other study ID #: MDCP-Lung
• Status: Completed
• Phase: N/A
• Start date: November 2004
• Est. completion date: January 2020

Study information

• Verified date: February 2020
• Source: University of Kentucky
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lung cancer is the number one cancer killer in Kentucky and has a very high incidence within the 5th Congressional District of Kentucky (110.8 cases per 100,000 in period 1996-2000). Surgical removal provides the best chance for cure. Unfortunately, the majority of lung cancer cases are detected in an advanced stage, when surgical resection is impossible. This leads to shorter survival rates and increased mortality rates for lung cancer, increased patient suffering, and greater cost to the healthcare system. Methods that favor earlier detection are therefore crucial for successful treatment. One such method, low-dose spiral computed tomography (CT) is being studied to determine whether its use as a screening method will lead to earlier detection and earlier intervention, perhaps impacting survival and mortality in lung cancer. This method has a modest sensitivity to detect lung cancer, but low specificity, which leads to many false positives and a low negative predictive value. The present study is designed to address both of these limitations by: 1) identifying individuals in the population at highest risk for developing lung cancer (due to smoking habits and decreased pulmonary function) for subsequent CT screening, and 2) performing biomarker testing in conjunction with the CT scan to improve the ability to discern individuals with benign lung nodules from those with malignant tumors. The 5th Congressional District of Kentucky has one of the highest rates of lung cancer in the nation and is an ideal location to test the validity (sensitivity and specificity), feasibility (negative and positive predictive value), and efficacy (stage distribution shift to earlier stage disease, increased survival, and decreased cancer-specific mortality) of these strategies to enhance early detection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 531
• Est. completion date: January 2020
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 55-75 years old.

• Identification of a primary care physician (can be identified by study staff if needed).

• FEV1/FVC <70% (GOLD 1 or higher COPD) (poor breathing function).

• > or = 40 pack-year current or former (within the last 10 years) tobacco use (i.e. heavy cigarette smoking history).

Exclusion Criteria:

• Enrolled in any other lung screening or lung cancer prevention trial.

• Chest CT within the prior 12 months.

• Inability to lie flat with arms raised above the head.

• Current or prior personal history of lung cancer.

• Prior history of cancer within the last five years or currently receiving treatment for cancer, except adequately treated non-melanomatous skin cancer or in-situ cervical cancer.

• Life expectancy of less than 5 years.

• Patients requiring supplemental oxygen.

• Inability to give informed consent.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Other:
• CT
Screening CT

Locations

Country	Name	City	State
United States	Hazard ARH Regional Medical Center	Hazard	Kentucky
United States	St. Claire Regional Medical Center	Morehead	Kentucky
United States	Highlands Regional Medical Center	Prestonsburg	Kentucky
United States	Lake Cumberland Regional Hospital	Somerset	Kentucky

Sponsors (3)

Lead Sponsor	Collaborator
Susanne Arnold	Kentucky Lung Cancer Research Program, Marty Driesler Cancer Project

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	test validity		5 years
Secondary	test feasibility		5 years
Secondary	test efficacy		5 years